ND0612 is a novel liquid formulation of levodopa/carbidopa (LD/CD) aimed to reduce motor complications in patients with advanced Parkinson’s Disease.
ND0612 is designed in low-dose (ND0612L) and high-dose (ND0612H), administered subcutaneously (just under the skin) through a mini-pump, enabling 24-hour continuous LD/CD administration.
In a phase II placebo controlled study, ND0612L was shown to maintain steady, therapeutic levodopa plasma concentrations that were associated with major changes in clinical parameters such as “OFF time” reduction when added to optimal oral standard of care.1
In a phase IIa study, ND0612H was shown to reach higher levodopa steady plasma levels,2 indicating that it may provide an effective alternative to current treatments requiring surgery, such as deep brain stimulation and LD/CD Intestinal Gel.
1. N. Giladi, Y. Caraco, T. Gurevich et al, 19th International Congress of Parkinson’s Disease and Movement Disorders. Late-Breaking Abstracts, Stable levodopa plasma levels with ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson’s Disease (PD) patients with motor fluctuations.
2. N. Giladi, Y. Caraco, T. Gurevich, et al. Presentation: O2114 -Pharmacokinetic profile of ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson’s Disease (PD) patients with motor fluctuations: results of a Phase IIa dose finding study , Eur J Neurol. 2015 Jun; 22 Suppl 1: p.66.